Table 4.

Studies evaluating percutaneous IRE in pancreatic cancer

Ref.	Patients	Median OS from IRE	Guidance	Major adverse events
Belfiore et al[64], 2015	20	13.951 mo	CT	0%
Narayanan et al[61], 2017	50	14.2 mo	CT	20%
Zhang et al[58], 2017	21	N/A	CT/US	0%
Scheffer et al[65], 2017	25	11 mo	CT	40%
Månsson et al[59], 2019	24	13.3 mo	US	25%
Flak et al[60], 2019	33	10.7 mo	US	20%
Ruarus et al[62], 2020	50	10 mo	CT	42%
Ma et al[51], 2020	33	19.8 mo	CT	9%

¹Mean value. CT: Computed tomography; US: Ultrasound.